Disruptive technologies such as iPSC generation and differentiation, gene editing, automation and drug discovery using artificial intelligence via deep learning algorithms have made human disease models for drug discovery a reality. Patient-derived material lies at the heart of this effort, which we at Ksilink access through our clinical partners. The models we are creating recapitulate the actual disease mechanisms in patients. Drug development, has been vertically accelerated as a result. Costs are lessened and chances of success bolstered. During this paradigm shift access to patient material and modelling know how is becoming a competitive game changer. Ksilink is designed to be at the forefront of this new development.